US FDA nod to keep Lupin on investor radars

Shares of Lupin will remain in focus after the company said it has received final approval from the US health regulator to sell generic diabetes management drug Pioglitazone Tablets in the US market. The announcement was made during the market’s closing hours on Wednesday. Lupin has said its subsidiary will shortly commence marketing the product, which has annual sales of $236 million in the US. The stock saw FII holding dip to 31.86 per cent (March end) from 31.92 per cent (December end).